Literature DB >> 11398141

Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus.

O Kordonouri1, R W James, B Bennetts, A Chan, Y L Kao, T Danne, M Silink, K Donaghue.   

Abstract

Paraoxonase (PON) is a high-density lipoprotein (HDL)-associated esterase, which may prevent the transformation of low-density lipoproteins (LDL) into biologically active, atherogenic particles. PON concentration and activity are affected by PON1 gene polymorphisms and found to be altered in type 2 diabetes patients with retinopathy. We investigated serum PON concentration, in vitro activity and polymorphism at position 54 (L/M, Leu-Met54) in 193 Caucasian adolescents and young adults (88 males, 105 females) with type 1 diabetes mellitus, as well as its relationship to the presence of retinopathy. An inverse linear correlation was found between blood glucose levels and both serum PON concentration (r = -.20, P =.017) and its activity (r = -0.17, P =.037). Patients with elevated blood glucose values (> or =10 mmol/L) had significantly lower levels of both PON concentration (P =.003) and activity (P =.028) than those with lower glucose levels. After adjusting for blood glucose and diabetes duration, PON activity was significantly higher in patients with different stages of retinopathy compared with those without retinopathy (P =.003). The L/L genotype was closely associated with the presence of retinopathy (P <.0001). These data show that young people with type 1 diabetes and the L/L polymorphism at position 54 of PON1 gene are more susceptible to retinal complications. However, the role of serum PON concentration and activity as a possible marker for monitoring late microvascular complications in these patients has to be established. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398141     DOI: 10.1053/meta.2001.23291

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

Review 1.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

2.  Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy.

Authors:  Mariusz Nowak; Tomasz Wielkoszyński; Bogdan Marek; Beata Kos-Kudła; Elzbieta Swietochowska; Lucyna Siemińska; Jacek Karpe; Dariusz Kajdaniuk; Joanna Głogowska-Szelag; Katarzyna Nowak
Journal:  Clin Exp Med       Date:  2009-12-11       Impact factor: 3.984

Review 3.  Paraoxonase gene polymorphisms, oxidative stress, and diseases.

Authors:  Hong-Liang Li; De-Pei Liu; Chih-Chuan Liang
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

4.  Paraoxonase-1 gene Q192R and L55M polymorphisms and risk of cardiovascular disease in Egyptian patients with type 2 diabetes mellitus.

Authors:  Dalia El-Lebedy; Mona Kafoury; Dalia Abd-El Haleem; Alshaymaa Ibrahim; Eman Awadallah; Ingy Ashmawy
Journal:  J Diabetes Metab Disord       Date:  2014-12-20

5.  The Associations between Paraoxonase 1 L55M/Q192R Genetic Polymorphisms and the Susceptibilities of Diabetic Macroangiopathy and Diabetic Microangiopathy: A Meta-Analysis.

Authors:  Chenfang Wu; Diling Wu; Minjie Lin; Yanjun Zhong
Journal:  Diabetes Ther       Date:  2018-07-09       Impact factor: 2.945

6.  Protective effect of paraoxonase 1 gene variant L55M in retinal vein occlusion.

Authors:  Huseyin Ortak; Erkan Söğüt; Omer Ateş; Unal Erkorkmaz; Ismail Benli; Ali Akbas; Selim Demir; Hüseyin Ozyurt
Journal:  Mol Vis       Date:  2013-02-25       Impact factor: 2.367

7.  Association between p.Leu54Met polymorphism at the paraoxonase-1 gene and plantar fascia thickness in young subjects with type 1 diabetes.

Authors:  Patricia H Gallego; Maria E Craig; Anthony C Duffin; Bruce Bennetts; Alicia J Jenkins; Sabine Hofer; Albert Lam; Kim C Donaghue
Journal:  Diabetes Care       Date:  2008-05-09       Impact factor: 19.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.